May 14, 2020
25th EHA Congress: Menarini Ricerche Discloses First Results From the Clinical Study on SEL24/MEN1703
Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Apr 14, 2020
Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Apr 07, 2020
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China
Feb 26, 2020
iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3Kd Inhibitor, IOA-244 for Solid Tumours
Dec 09, 2019
61st ASH Congress 2019: Menarini Ricerche Presents the Latest Updates About the First In Human Clinical Trial of SEL24/MEN1703
Nov 05, 2019
Curis Reports Third Quarter 2019 Financial Results
Oct 03, 2019
MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
Sep 23, 2019
ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer
Sep 12, 2019
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
Jul 23, 2019
The PI3K inhibitors market is forescasted to grow at a CAGR of about 5% during the forecast period
Jul 15, 2019
Umbralisib (TG Therapeutics/Rhizen) Drug Overview & Product Profiles 2017-2018 & 2019-2026
Jul 12, 2019
Zydelig (idelalisib; Gilead) Drug Overview 2019: An Oral, Highly Selective Inhibitor of the Phosphoinositide 3-Kinase (PI3K) Isoform p110-delta
Jul 01, 2019
Global Aliqopa (Copanlisib; Bayer) Drug Profile 2019: A Small Molecule Phosphoinositide 3-Kinase (PI3K) Inhibitor with High Selectivity for the p110-alpha/delta Catalytic Subunits
Jun 05, 2019
Targeted Cancer Therapeutics Market, 2025
Jun 03, 2019
MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2019
FDA approves first PI3K inhibitor for breast cancer
May 23, 2019
Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology
May 08, 2019
New positive data from phase IIa trial in brain cancer patients
Mar 27, 2019
Bayer Data at AACR 2019 Underscores Company's Commitment to Advancing the Future of Cancer Care